|Bid||0.0590 x 6348300|
|Ask||0.0680 x 5187600|
|Day's range||0.0550 - 0.0550|
|52-week range||0.0470 - 0.1600|
|Beta (5Y monthly)||1.07|
|PE ratio (TTM)||N/A|
|Earnings date||29 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
2021 has been a significant year for Anatara Lifesciences Limited (ASX:ANR), as we made steps towards progressing our human health products towards clinical trials, successfully completed animal health studies and progressed licensing discussions.
ObvioHealth, a global Virtual Research Organization (VRO), today announces the launch of a first-of-its kind clinical trial in Australia, using a combination of in-home data collection methods that will reduce, and in some cases, eliminate the need for follow-up visits to clinics.